** U.S.-listed shares of Australia's Telix Pharmaceuticals TLX.AX, TLX.O up 30% at $25.33
** Co says the Norway's regulatory authority has granted marketing authorization to co's prostate cancer imaging agent, Illuccix
** Illuccix is already approved by the U.S. FDA in Oct. 2024
** TLX has more than doubled in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatol@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.